

REMARKS

Upon entry of the present amendment, claims 1-9 and 14-17 are pending. In the present amendment, Applicants have amended the priority claim in the specification pursuant to MPEP § 201.11(III)(G). Applicants have canceled claims 10-13 and 18-52 without prejudice or disclaimer. Applicants have amended claims 1-9 and 14. The amendments to the claims are supported by the claims as originally filed and in the specification, e.g., at page 2, lines 26-28; page 4, lines 31-34; page 5, line 24, through page 6, line 30; page 8, lines 14-20; page 17, line 33, through page 18, line 4; and page 18, lines 27-32. No new matter is added by the foregoing amendments.

In the Office Action, the Examiner required restriction to one of the following groups of claims under 35 U.S.C. § 121:

- Group I: Claims 1-17, allegedly drawn to full length nucleic acids, vectors, host cells, and methods of recombinantly producing protein
- Group II: Claims 18-26 and 31 (in part), allegedly drawn to polypeptides
- Group III: Claims 27 and 28 and 31 (in part), allegedly drawn to antibodies
- Group IV: Claims 29 and 30 and 31 (in part), allegedly drawn to agonists and antagonists
- Group V: Claim 32, allegedly drawn to an oligonucleotide
- Group VI: Claims 33-40, allegedly drawn to methods of detecting polypeptides
- Group VII: Claims 41-46, allegedly drawn to methods of linking a bioactive molecule to a polypeptide

Group VIII: Claims 47-50, allegedly drawn to methods of modulating the activity of
a cell

Group IX: Claims 51-52, allegedly drawn to methods for detecting the presence
of a tumor in an animal

Applicants elect Group I, claims 1-17. Applicants note that claims 10-13 are
canceled by the above amendments.

Please grant any extensions of time and charge any additional required fees to
Deposit Account No. 07-0630. The Examiner is invited to contact the undersigned at
(650) 467-0594 to resolve any issues in the above matter.

Respectfully submitted,

GENENTECH, INC.

Dated: October 16, 2006

By: *Danielle Pasqualone*
Danielle M. Pasqualone, Ph.D.
Reg. No. 43,847
Phone: (650) 467-0594
Fax: (650) 952-9881